



Clinical trial results: Supra Sacral Parallel Shift - ultrasound/MR image fusion guided lumbosacral plexus block

Summary

EudraCT number	2013-004013-41
Trial protocol	DK
Global end of trial date	08 November 2015

Results information

Result version number	v1 (current)
This version publication date	20 November 2016
First version publication date	20 November 2016

Trial information

Trial identification

Sponsor protocol code	AUH-TFB-SSPS
-----------------------	--------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02593370
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Thomas Fichtner Bendtsen
Sponsor organisation address	Dep. of Anaesthesiology and Intensive Care, Aarhus University Hospital, Nørrebrogade 44, Aarhus C, Denmark, DK-8000
Public contact	Clinical Trial Information - SSPS, Thomas Fichtner Bendtsen, +45 51542997, tfb@dadlnet.dk
Scientific contact	Clinical Trial Information - SSPS, Thomas Fichtner Bendtsen, +45 51542997, tfb@dadlnet.dk

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	24 September 2016
Is this the analysis of the primary completion data?	Yes
Primary completion date	08 November 2015
Global end of trial reached?	Yes
Global end of trial date	08 November 2015
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The main objective of the trial is to complete a blinded randomised controlled trial with a single injection block of the lower part of the lumbar plexus (L2, L3, L4) and the upper part of the sacral plexus (L4, L5, S1) with regard to proximal analgesia of the femoral nerve, the obturator nerve, and the lumbosacral trunk with ultrasound/MR image fusion guided vs. ultrasound guided Supra Sacral Parallel shift-technique by estimating motor block as a proxy marker of sensory block of the terminal nerves innervation in healthy volunteers.

As an exploratory analysis, we examined compartmentalised injectate spread.

Protection of trial subjects:

The trial subjects were asked about their general well-being and any prior disease and discomfort during enrollment and upon arrival to as well as departure from the trial venue on each experimental day. The trial subjects were monitored with 3-lead electrocardiography, non-invasive pressure, and pulse oximetry from five minutes before the pre-scan to five minutes after completed intervention. During each intervention, the research anaesthetist and the assistant communicated with the trial subject reassuring his/her well-being. Immediately after completed intervention, the maximal discomfort of the trial subject during the procedure was assessed on a numeric rating scale (NRS 0-10).

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	03 October 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Denmark: 26
Worldwide total number of subjects	26
EEA total number of subjects	26

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23	0

months)	
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	26
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

All volunteers were recruited through a Danish website for research volunteers from 3 October 2015 to 24 October 2015.

Pre-assignment

Screening details:

26 volunteers were screened and 26 volunteers were included in the study.

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind ^[1]
Roles blinded	Data analyst, Assessor

Blinding implementation details:

In addition we strived to blind the trial subjects with identical trial setup.

Arms

Are arms mutually exclusive?	No
Arm title	SSPS US/MR

Arm description:

All included trial subjects received a lumbosacral plexus block with the Suprasacral Parallel Shift (SSPS) technique guided by ultrasound/MRI fusion either on the first or the second trial day (randomised).

Arm type	Experimental
Investigational medicinal product name	Lidokain-adrenalin SAD
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Perineural use

Dosage and administration details:

20 ml 2% lidocaine with 0.0005% adrenaline was injected.

Investigational medicinal product name	Dotarem
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion in pre-filled syringe
Routes of administration	Perineural use

Dosage and administration details:

0.13 ml Dotarem (279.3 mg gadoterate meglumine) was added to the lidocaine-adrenaline prior to injection in order to enhance visualisation of the anatomical spread of lidocaine-adrenaline on MRI after the intervention.

Arm title	SSPS US
------------------	---------

Arm description:

All included trial subjects received a lumbosacral plexus block with the Suprasacral Parallel Shift (SSPS) technique either on the first or the second trial day (randomised).

Arm type	Active comparator
Investigational medicinal product name	Lidokain-adrenalin SAD
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Perineural use

Dosage and administration details:

20 ml 2% lidocaine with 0.0005% adrenaline was injected.

Investigational medicinal product name	Dotarem
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion in pre-filled syringe
Routes of administration	Perineural use

Dosage and administration details:

0.13 ml Dotarem (279.3 mg gadoterate meglumine) was added to the lidocaine-adrenaline prior to injection in order to enhance visualisation of the anatomical spread of lidocaine-adrenaline on MRI after the intervention.

Notes:

[1] - The roles blinded appear to be inconsistent with a double blind trial.

Justification: The observers and analysts of data were blinded and we strived to blind the trial subjects with identical trial setup and by not revealing the guidance technique (US/MRI or US) of the intervention during the trial.

Number of subjects in period 1	SSPS US/MR	SSPS US
Started	26	26
Completed	26	26

Baseline characteristics

Reporting groups

Reporting group title

Overall trial

Reporting group description: -

Reporting group values	Overall trial	Total	
Number of subjects	26	26	
Age categorical			
Units: Subjects			
Adults (18-64 years)	26	26	
Age continuous			
Units: years			
median	22		
inter-quartile range (Q1-Q3)	22 to 24	-	
Gender categorical			
Units: Subjects			
Female	12	12	
Male	14	14	
Weight			
Units: kg			
arithmetic mean	73.2		
standard deviation	± 11.7	-	
Height			
Units: cm			
arithmetic mean	178		
standard deviation	± 8.1	-	
Body mass index			
Units: kg/m2			
arithmetic mean	23.4		
standard deviation	± 2.7	-	

End points

End points reporting groups

Reporting group title	SSPS US/MR
Reporting group description: All included trial subjects received a lumbosacral plexus block with the Suprasacral Parallel Shift (SSPS) technique guided by ultrasound/MRI fusion either on the first or the second trial day (randomised).	
Reporting group title	SSPS US
Reporting group description: All included trial subjects received a lumbosacral plexus block with the Suprasacral Parallel Shift (SSPS) technique either on the first or the second trial day (randomised).	

Primary: Block success

End point title	Block success
End point description: A block was considered successful when the subject had motor blockade of the femoral and obturator nerves as well as the lumbosacral trunk. Motor blockade was defined as post-block muscle force < baseline muscle force of knee extension (femoral nerve), hip adduction (obturator nerve), and lumbosacral trunk (hip abduction), respectively.	
End point type	Primary
End point timeframe: Baseline muscle force was assessed upon arrival on the first experimental day. Post-block muscle force was assessed 40 min after completed intervention.	

End point values	SSPS US/MR	SSPS US		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26	26		
Units: Number of subjects	23	23		

Statistical analyses

Statistical analysis title	Block success
Comparison groups	SSPS US/MR v SSPS US
Number of subjects included in analysis	52
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 1
Method	Mcneemar
Parameter estimate	Difference in paired proportions
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.22
upper limit	0.22

Secondary: Block preparation time

End point title	Block preparation time
-----------------	------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Assessed prior to intervention. Defined as the time from placement of the subject on the bed to completed pre-scanning and co-registration of ultrasound and MRI.

End point values	SSPS US/MR	SSPS US		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26	26		
Units: second				
median (inter-quartile range (Q1-Q3))	686 (552 to 1023)	196 (167 to 228)		

Statistical analyses

No statistical analyses for this end point

Secondary: Block procedure time

End point title	Block procedure time
-----------------	----------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Assessed as the time from placement of the probe on the skin after completed preparations to withdrawal of the block needle after completed injection.

End point values	SSPS US/MR	SSPS US		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26	26		
Units: second				
median (inter-quartile range (Q1-Q3))	333 (254 to 439)	216 (176 to 294)		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of needle insertions

End point title	Number of needle insertions
-----------------	-----------------------------

End point description:

The number of block needle insertions was defined as the number of retractions of the block needle followed by advancement regardless of the number of skin insertions.

End point type	Secondary
----------------	-----------

End point timeframe:

Counted from the start of the block procedure time to the end of injection.

End point values	SSPS US/MR	SSPS US		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26	26		
Units: Number				
median (inter-quartile range (Q1-Q3))	4.5 (3 to 7)	5 (3 to 7)		

Statistical analyses

No statistical analyses for this end point

Secondary: Needle insertion point

End point title	Needle insertion point
-----------------	------------------------

End point description:

The block needle insertion point was estimated as the horizontal distance (cm) from the needle insertion point in the skin to the lumbar midline.

End point type	Secondary
----------------	-----------

End point timeframe:

Measured immediately after completed injection.

End point values	SSPS US/MR	SSPS US		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26	26		
Units: cm				
median (inter-quartile range (Q1-Q3))	4 (4 to 5)	6 (3 to 7)		

Statistical analyses

No statistical analyses for this end point

Secondary: Needle depth

End point title	Needle depth
-----------------	--------------

End point description:

The distance from skin to the block needle tip was estimated as the distance (cm) from the block needle insertion point in the skin to the block needle tip gauged by reading of the cm markings on the needle shaft.

End point type	Secondary
----------------	-----------

End point timeframe:

Measured immediately prior to injection of study medicine.

End point values	SSPS US/MR	SSPS US		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26	26		
Units: cm				
median (inter-quartile range (Q1-Q3))	8 (7 to 9)	8 (7 to 8.5)		

Statistical analyses

No statistical analyses for this end point

Secondary: Minimal electrical nerve stimulation

End point title	Minimal electrical nerve stimulation
-----------------	--------------------------------------

End point description:

The minimum electrical nerve stimulation level in mA required to trigger a response was measured in order to confirm the position of the block needle tip before injection.

End point type	Secondary
----------------	-----------

End point timeframe:

Assessed immediately prior to injection.

End point values	SSPS US/MR	SSPS US		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26	26		
Units: mA				
median (inter-quartile range (Q1-Q3))	0.5 (0.5 to 0.5)	0.5 (0.4 to 0.5)		

Statistical analyses

No statistical analyses for this end point

Secondary: Response on electrical nerve stimulation

End point title	Response on electrical nerve stimulation
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Assessed immediately prior to injection.

End point values	SSPS US/MR	SSPS US		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26	26		
Units: Number of subjects				
Quadriceps femoris	4	4		
Adductor	0	1		
Other motor	0	0		
Paraesthesia	2	0		
None	20	21		

Statistical analyses

No statistical analyses for this end point

Secondary: Procedural discomfort

End point title	Procedural discomfort
-----------------	-----------------------

End point description:

The trial subject's discomfort during block procedure was assessed on a numeric rating scale (NRS) 0-10, where 0 = no discomfort and 10 = worst possible discomfort.

End point type	Secondary
----------------	-----------

End point timeframe:

Assessed immediately after completed intervention.

End point values	SSPS US/MR	SSPS US		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26	26		
Units: NRS units				
median (inter-quartile range (Q1-Q3))	2 (1 to 3)	3 (2 to 4)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change in mean arterial pressure (MAP)

End point title	Change in mean arterial pressure (MAP)
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

ΔMAP was measured as the change of MAP from the time immediately prior to pre-scanning to 5 minutes after completed intervention.

End point values	SSPS US/MR	SSPS US		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26	26		
Units: mmHg				
arithmetic mean (standard deviation)	0.23 (± 12.77)	-4.5 (± 10.44)		

Statistical analyses

No statistical analyses for this end point

Secondary: Perineural spread of injectate

End point title	Perineural spread of injectate
-----------------	--------------------------------

End point description:

Perineural spread of local anaesthetic was assessed as present when visual contact between the local anaesthetic and the nerve on MRI was confirmed.

End point type	Secondary
----------------	-----------

End point timeframe:

Assessed by MRI recorded 15 min after completed injection.

End point values	SSPS US/MR	SSPS US		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26	26		
Units: Number of subjects				
Anterior ramus L2	14	11		
Anterior ramus L3	21	21		
Anterior ramus L4	22	25		
Anterior ramus L5	10	18		
Anterior ramus S1	5	8		
Femoral nerve	16	13		
Obturator nerve	14	11		
Lateral femoral cutaneous nerve	16	11		
Lumbosacral trunk	10	15		

Statistical analyses

No statistical analyses for this end point

Secondary: Epidural spread of injectate

End point title	Epidural spread of injectate
-----------------	------------------------------

End point description:

Epidural spread was assessed to be present when circumferential epidural spread of the injectate was observed on MRI and decreased or absent sensation for cold was observed in at least one pair of bilateral dermatomes during the sensory mapping.

End point type	Secondary
----------------	-----------

End point timeframe:

Epidural spread of local anaesthetics was assessed on MRI sampled 15 minutes after completed intervention and during sensory mapping 50 minutes after completed intervention.

End point values	SSPS US/MR	SSPS US		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26	26		
Units: Number of subjects	3	5		

Statistical analyses

No statistical analyses for this end point

Secondary: Sensory blockade - Cold

End point title	Sensory blockade - Cold
-----------------	-------------------------

End point description:

Sensory block for cold in the dermatomes Th12-S3 and in the skin area innervated by the lateral femoral cutaneous nerve, respectively, was assessed as present when the somatosensation for cold was decreased/absent.

End point type	Secondary
----------------	-----------

End point timeframe:

Assessed 50 minutes after completed intervention.

End point values	SSPS US/MR	SSPS US		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26	26		
Units: Number of subjects				
Th12	2	0		
L1	4	3		
L2	8	10		
L3	18	16		
L4	18	15		
L5	10	11		

S1	16	14		
S2	5	7		
S3	5	8		
Lateral femoral cutaneous nerve	13	9		

Statistical analyses

No statistical analyses for this end point

Secondary: Sensory blockade - Warmth

End point title	Sensory blockade - Warmth
-----------------	---------------------------

End point description:

Sensory block for warmth in the dermatomes Th12-S3 and in the skin area innervated by the lateral femoral cutaneous nerve, respectively, was assessed as present when the somatosensation for warmth was decreased/absent.

End point type	Secondary
----------------	-----------

End point timeframe:

Assessed 50 minutes after completed intervention.

End point values	SSPS US/MR	SSPS US		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26	26		
Units: Number of subjects				
Th12	1	1		
L1	2	4		
L2	9	10		
L3	13	16		
L4	17	14		
L5	9	12		
S1	16	18		
S2	7	10		
S3	5	7		
Lateral femoral cutaneous nerve	14	10		

Statistical analyses

No statistical analyses for this end point

Secondary: Sensory blockade - Touch

End point title	Sensory blockade - Touch
-----------------	--------------------------

End point description:

Sensory block for touch in the dermatomes Th12-S3 and in the skin area innervated by the lateral femoral cutaneous nerve, respectively, was assessed as present when the somatosensation for touch was decreased/absent.

End point type	Secondary
----------------	-----------

End point timeframe:

Assessed 50 minutes after completed intervention.

End point values	SSPS US/MR	SSPS US		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26	26		
Units: Number of subjects				
Th12	4	1		
L1	9	6		
L2	9	11		
L3	7	9		
L4	13	13		
L5	8	10		
S1	3	10		
S2	8	7		
S3	7	9		
Lateral femoral cutaneous nerve	16	10		

Statistical analyses

No statistical analyses for this end point

Secondary: Sensory blockade - Pain

End point title	Sensory blockade - Pain
-----------------	-------------------------

End point description:

Sensory block for pinprick (pain) in the dermatomes Th12-S3 and in the skin area innervated by the lateral femoral cutaneous nerve, respectively, was assessed as present when the somatosensation for pinprick was decreased/absent.

End point type	Secondary
----------------	-----------

End point timeframe:

Assessed 45 minutes after completed intervention.

End point values	SSPS US/MR	SSPS US		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26	26		
Units: Number of subjects				
Th12	7	2		
L1	7	4		
L2	12	11		
L3	15	9		
L4	13	14		
L5	8	10		
S1	8	12		

S2	7	6		
S3	7	8		
Lateral femoral cutaneous nerve	17	10		

Statistical analyses

No statistical analyses for this end point

Secondary: Cmax of p-lidocaine

End point title	Cmax of p-lidocaine
-----------------	---------------------

End point description:

Maximum concentration (Cmax) of plasma lidocaine (p-lidocaine).

End point type	Secondary
----------------	-----------

End point timeframe:

Cmax of p-lidocaine was assessed in blood sampled at 0, 5, 10, 20, 40, 60, and 90 minutes after intervention.

End point values	SSPS US/MR	SSPS US		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26	25		
Units: µg*ml-1				
arithmetic mean (standard deviation)	1.28 (± 0.35)	1.21 (± 0.4)		

Statistical analyses

No statistical analyses for this end point

Secondary: Tomc of p-lidocaine

End point title	Tomc of p-lidocaine
-----------------	---------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Time to Cmax was estimated in the period 0-90 minutes after completed intervention.

End point values	SSPS US/MR	SSPS US		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26	25		
Units: minute				
median (inter-quartile range (Q1-Q3))	60 (40 to 60)	60 (40 to 60)		

Statistical analyses

No statistical analyses for this end point

Secondary: P-lidocaine concentration-area under the curve

End point title	P-lidocaine concentration-area under the curve
End point description:	
End point type	Secondary
End point timeframe:	
Assessed in the period 0-90 minutes after completed intervention.	

End point values	SSPS US/MR	SSPS US		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26	25		
Units: µg*min*ml-1				
arithmetic mean (standard deviation)	89.1 (± 25.5)	87.3 (± 30.8)		

Statistical analyses

No statistical analyses for this end point

Secondary: Cost-effectiveness

End point title	Cost-effectiveness
End point description:	
Cost-effectiveness of the interventions was estimated as the difference in mean marginal cost for the ultrasound/MRI fusion vs. the ultrasound guided Suprasacral Parallel Shift technique.	
End point type	Secondary
End point timeframe:	
Calculated in the end of the data analysis after last subject last visit.	

End point values	SSPS US/MR	SSPS US		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26	26		
Units: GBP				
number (not applicable)	22.91	0		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Continuous and systematic assessment of adverse events from upon arrival to discharge on each experimental day. All trial subjects were urged to self-report any adverse events between the experimental days and after discharge.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	19.0

Reporting groups

Reporting group title	SSPS US/MR
Reporting group description: -	
Reporting group title	SSPS US
Reporting group description: -	

Serious adverse events	SSPS US/MR	SSPS US	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 26 (0.00%)	0 / 26 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	SSPS US/MR	SSPS US	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 26 (11.54%)	3 / 26 (11.54%)	
Vascular disorders			
Hypotension			
subjects affected / exposed	0 / 26 (0.00%)	1 / 26 (3.85%)	
occurrences (all)	0	1	
Syncope			
subjects affected / exposed	1 / 26 (3.85%)	1 / 26 (3.85%)	
occurrences (all)	1	1	
Lightheadedness			
subjects affected / exposed	1 / 26 (3.85%)	2 / 26 (7.69%)	
occurrences (all)	1	2	
Flushing			

subjects affected / exposed occurrences (all)	0 / 26 (0.00%) 0	1 / 26 (3.85%) 1	
Musculoskeletal and connective tissue disorders Sprained ankle alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 26 (3.85%) 1	0 / 26 (0.00%) 0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported